R-azasetron besylate - Sensorion

Drug Profile

R-azasetron besylate - Sensorion

Alternative Names: R-azasetron besylate; SENS 401

Latest Information Update: 12 Jun 2017

Price : $50

At a glance

  • Originator Sensorion
  • Developer Sensorion; Simbec Research
  • Class Heterocyclic bicyclo compounds; Oxazines; Small molecules
  • Mechanism of Action Serotonin 3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Sensorineural hearing loss
  • New Molecular Entity No

Highest Development Phases

  • Phase I Sensorineural hearing loss
  • Preclinical Hearing loss

Most Recent Events

  • 02 May 2017 Pharmacodynamics data from a preclinical study in Hearing loss (cisplatin-induced) released by Sensorion
  • 26 Apr 2017 Preclinical trials in Hearing loss (Prevention) in France (PO) before April 2017
  • 24 Nov 2016 SENS 401 receives Orphan Drug status for Sensorineural hearing loss in European Union
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top